A few days ago, we were reached by the thrilling news that our client, and MedTech start-up, Mensia Technologies had just raised 1.3 million euros to introduce their revolutionary digital and therapeutic device in Europe, a major step forward in the combat against Attention Deficit Disorders.
The French company leads the new booming category of digital therapeutics with a neurofeedback technique that is noninvasive, can be used at home and works without drug distribution. MENSIA KOALA treats children and adolescents with Attention Deficit Disorders (ADHD) with or without hyperactivity, by using a unique medical device consisting of a therapeutic video game on an interactive tablet connected to the brain activity.
Children learn to control their attention by exercising 3 times a week for 4 months of treatment. Visual feedback given during the game, allows the children to learn, control and create automatisms. Significant reduction of their attention deficit and/or hyperactivity with long-lasting effects has been observed and the benefit versus risk ratio is extremely favourable and has not shown adverse events compared to the amphetamines drugs traditionally used for treatment as for example Ritaline.
Six years of R&D and millions of dollars invested has lead to the grant of a CE mark class IIa in Europe. After launching sales in France, next step on the company roadmap is expanding the network of resellers in the rest of Europe followed by another investment round to back up the deployment in the U.S. along with plans for another medical device to treat chronic low back pain.
Inspiralia has been working with Mensia Technologies in relation to the Newrofeed project, a clinical trial that is currently being conducted in five European countries to compare Mensia Koala with methylphenidate, the current standard of ADHD care. It is the largest clinical study of its kind ever undertaken.